BGPT: Paper Review: Skeletal Muscle and Kidney Crosstalk in Chronic Kidney Disease

Explore by Goal

Quick Explanation Copied

Core claim (skeptical take): This narrative review argues that CKD-associated skeletal muscle wasting is partly driven by kidney-derived “renalkines” (especially activin A) and that muscle-derived factors (myokines/miRs/exosomal RNAs, irisin, MG53) can feed back to influence renal fibrosis and function—summarizing evidence across patient correlations and multiple nephropathy models.

Long Explanation

Paper Review (Narrative): Skeletal Muscle and Kidney Crosstalk in Chronic Kidney Disease

Date (paper): 2022-10-26. DOI: 10.33594/000000578.

Visual: Disease → Crosstalk → Pathway “wiring diagram” (as claimed)

Important skepticism: this “wiring diagram” mirrors what the review claims, not necessarily what is proven in humans. The review itself flags mechanistic uncertainty for multiple factors and emphasizes measurement controversies (notably irisin ELISA specificity).

Visual: CKD prevalence & sarcopenia burden (as reported in the review)

The review states CKD prevalence and a range/uncertainty for sarcopenia rates depending on definitions/tools.

Visual: Claimed “factor roster” and evidence posture (known vs asserted vs uncertain)

This table is not a graded meta-analysis. It summarizes the review’s own presentation of evidence type (correlation, preclinical mechanistic, and translation caveats).

Factor	Direction (as framed)	Mechanistic theme emphasized	Translation confidence (review’s own cautions)
Activin A	Kidney → muscle (renalkine)	ActRIIB → Akt–FoxO proteolysis; Smad2/3 myogenesis inhibition	Mechanistic support in models; human mechanistic causality described as dependent on preclinical evidence
Myostatin	Muscle → systemic; possible kidney effects	Smad2/3 signaling; muscle wasting programs; kidney implications framed as requiring more evidence	Human associations inconsistent for muscle outcomes; kidney-specific evidence described as limited
miR-23/27/26/29	Muscle → kidney (exosomes/transfer)	Exosomal/AAV miR delivery reduces renal fibrosis markers; frequently ties to TGFβ/Smad attenuation (as described)	Causality from endogenous CKD-associated miR decline not established; exercise-responsiveness inconsistent
Irisin	Muscle → kidney	TGFβ signaling interference; Smad2/3 phosphorylation inhibition (as framed)	Measured associations + model effects, but strong controversy: ELISA specificity and other biological/analytical issues
MG53 (TRIM72)	Muscle → kidney	Membrane repair / inflammation and kidney fibrosis modulation (as described)	Preclinical evidence; translation cautioned by potential insulin-signaling effects and mixed metabolic findings

Visual: “What is known” vs “what the review infers” (causality stress test)

The review repeatedly distinguishes:

Known (as presented): CKD is associated with muscle wasting/sarcopenia and muscle fiber dysfunction; kidney dysfunction contributes to muscle proteolysis via insulin-signaling impairment and related pathways (as reviewed).
Inferred/conditional: that specific secreted molecules account for part of the inter-organ link; that endogenous CKD-driven changes in factor levels are causal rather than merely correlated.
Uncertain/contested: measurement validity (irisin), inconsistent human association patterns (myostatin), and whether exogenous delivery equals physiological causation (miRs).

Critical appraisal (skeptical, evidence-based)

Strengths

The review organizes crosstalk by named candidate molecules and highlights recurring signaling hubs (e.g., ActRIIB pathways; TGFβ/Smad2/3 as a recurrent anti-fibrotic axis) rather than staying purely descriptive.
It flags translational friction points (especially irisin measurement specificity) which are commonly underestimated when readers focus only on directionality from models.

Red flags / blind spots

Narrative (not systematic) selection risk: the paper is explicitly a narrative review, so included mechanistic studies may not reflect the full evidentiary distribution; readers could over-weight salient factors (e.g., TGFβ/Smad hubs) due to citation/availability patterns.
Causality asymmetry: exogenous miR or protein delivery shows feasibility of reversing endpoints, but does not prove that endogenous CKD-relevant miR/protein declines are causally upstream of the disease phenotype in humans. The review acknowledges this limitation directly for miRs.
Human heterogeneity: CKD stages, comorbidities, and measurement assays vary across cited studies; the review itself notes broad sarcopenia incidence variability depending on definitions and tools.
Irisin assay-driven uncertainty: if ELISA-based concentrations are systematically biased by specificity issues, then correlations with CKD progression could be partly analytical artifacts rather than biological regulation. The review explicitly raises this concern.

Practical value: what a researcher can take away

Best-supported pathway anchor in this review is the convergence on signaling programs (ActRIIB → Akt–FoxO and Smad2/3; and TGFβ/Smad2/3 themes in kidney fibrosis) rather than a single biomarker claim.

Testable implications (what would change the picture)

Necessity tests: demonstrate that endogenous CKD-driven changes in the candidate molecule/miR are required for muscle wasting (e.g., tissue-specific knockdown/neutralization rather than only exogenous supplementation).
Measurement validation: establish that the assays for circulating factors (especially irisin) produce reproducible, specific signals across cohorts; otherwise cross-study reproducibility will remain weak.
Bidirectionality boundaries: determine when kidney targeting in muscle changes renal endpoints versus when improvements are secondary to systemic changes (e.g., altered clearance, nutrition, inflammation). The review indicates bidirectionality exists in models (activin A inhibition in muscle improves kidney structure/function).

Author reviews (BGPT)

Feedback:

Updated: April 29, 2026